Alzheimer’s disease is often broadly referred to as “Type 3 diabetes,” because it’s thought that glucose processing goes haywire in the neurodegenerative disease, just as it does in diabetes.

A new National Institutes of Health study adds some credence to that theory, finding that glitches in the way the brain breaks down glucose — a process called glycolysis — seem to correspond with more severe symptoms in patients with Alzheimer’s.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy